Clinical Trial: Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome
Study Status: Completed
Recruit Status: RECRUITING
Condition: Down Syndrome
Study Type: INTERVENTIONAL
Official Title: Phase II Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome
Brief Summary:
This trial protocol is designed to evaluate primarily whether the use of sargramostim (recombinant human GM-CSF), administered five days per week for four consecutive weeks (20 treatment days), will be well tolerated by and safe for use in young adult participants with Down syndrome.
Read more